Zobrazeno 1 - 10
of 76
pro vyhledávání: '"Craig A, Clifford"'
Autor:
Gerry Polton, Juan F. Borrego, Francisco Clemente-Vicario, Craig A. Clifford, Dariusz Jagielski, Martin Kessler, Tetsuya Kobayashi, Didier Lanore, Felisbina L. Queiroga, Annika Tranaeus Rowe, Péter Vajdovich, Philip J. Bergman
Publikováno v:
Frontiers in Veterinary Science, Vol 11 (2024)
Externí odkaz:
https://doaj.org/article/76aa816d76b546d996e92a364dd27418
Autor:
Gerry Polton, Juan F. Borrego, Francisco Clemente-Vicario, Craig A. Clifford, Dariusz Jagielski, Martin Kessler, Tetsuya Kobayashi, Didier Lanore, Felisbina L. Queiroga, Annika Tranaeus Rowe, Péter Vajdovich, Philip J. Bergman
Publikováno v:
Frontiers in Veterinary Science, Vol 11 (2024)
Melanoma of the dog and cat poses a clinical challenge to veterinary practitioners across the globe. As knowledge evolves, so too do clinical practices. However, there remain uncertainties and controversies. There is value for the veterinary communit
Externí odkaz:
https://doaj.org/article/95f9ed6e9a7e4fc697afcaa10b76d0c4
Autor:
Kristen M. Weishaar, Zachary M. Wright, Mona P. Rosenberg, Gerald S. Post, Jennifer A. McDaniel, Craig A. Clifford, Brenda S. Phillips, Philip J. Bergman, Elissa K. Randall, Anne C. Avery, Douglas H. Thamm, Abigail A. Christman Hull, Cathy M. Gust, Ann R. Donoghue
Publikováno v:
Journal of Veterinary Internal Medicine, Vol 36, Iss 1, Pp 215-226 (2022)
Abstract Background Rabacfosadine (RAB, Tanovea‐CA1) is a novel chemotherapy agent conditionally approved for the treatment of lymphoma in dogs. Hypothesis/Objectives To determine the efficacy and safety of RAB in dogs with lymphoma. Animals One hu
Externí odkaz:
https://doaj.org/article/a5afe027f0024984bddc158f569fc1e0
Autor:
Jacob R. Cawley, Zachary M. Wright, Karri Meleo, Gerald S. Post, Craig A. Clifford, Kathryn R. Vickery, David M. Vail, Philip J. Bergman, Douglas H. Thamm
Publikováno v:
Journal of Veterinary Internal Medicine, Vol 34, Iss 2, Pp 882-889 (2020)
Abstract Background Rabacfosadine (RAB), a novel antineoplastic agent conditionally licensed for the treatment of lymphoma in dogs, is efficacious in both naïve and previously treated dogs. Its use in combination with L‐asparaginase (L‐ASP) has
Externí odkaz:
https://doaj.org/article/1ce026be3cc946338fa82f8615860027
Autor:
Rebecca C. Smedley, Laura Bongiovanni, Cynthia Bacmeister, Craig A. Clifford, Neil Christensen, Jennifer M. Dreyfus, Joy M. Gary, Alana Pavuk, Peter H. Rowland, Christine Swanson, Chelsea Tripp, J. Paul Woods, Philip J. Bergman
Publikováno v:
Veterinary and Comparative Oncology. 20:739-751
One of the primary objectives of the Oncology Pathology Working Group (OPWG) is for oncologists and pathologists to collaboratively generate consensus documents to standardize aspects of and provide guidelines for veterinary oncologic pathology. Cons
Publikováno v:
Veterinary Surgical Oncology. :17-68
Autor:
Margaret L. Musser, Craig A. Clifford, Philip J. Bergman, Laura S. Treml, Lydia C. Cook McAnulty, Elizabeth A. McNiel, Chad M. Johannes
Publikováno v:
Veterinary record open. 9(1)
Canine peripheral nodal T-cell lymphoma is considered chemotherapy resistant and carries a relatively poor prognosis. Prospective evaluations reporting the impact of chemotherapy on progression-free survival (PFS) and overall survival time for dogs w
Autor:
Chelsea D. Tripp, Margaret L. Musser, Craig A. Clifford, P. J. Bergman, Chad M Johannes, Erika P. Berger
Publikováno v:
Veterinary and Comparative Oncology
Canine osteosarcoma (OSA) is an aggressive bone tumor in dogs. Standard-of-care treatment typically results in relatively short survival times; thus, alternative treatments are needed to confer a survival advantage. It has been shown that OSA is an i
Autor:
K. R. Vickery, Jacob R. Cawley, Douglas H. Thamm, Karri Meleo, Philip J. Bergman, G. S. Post, Z. M. Wright, David M. Vail, Craig A. Clifford
Publikováno v:
Journal of Veterinary Internal Medicine
Journal of Veterinary Internal Medicine, Vol 34, Iss 2, Pp 882-889 (2020)
Journal of Veterinary Internal Medicine, Vol 34, Iss 2, Pp 882-889 (2020)
Background Rabacfosadine (RAB), a novel antineoplastic agent conditionally licensed for the treatment of lymphoma in dogs, is efficacious in both naive and previously treated dogs. Its use in combination with L-asparaginase (L-ASP) has not been studi
Autor:
Kristen M. Weishaar, Zachary M. Wright, Mona P. Rosenberg, Gerald S. Post, Jennifer A. McDaniel, Craig A. Clifford, Brenda S. Phillips, Philip J. Bergman, Elissa K. Randall, Anne C. Avery, Douglas H. Thamm, Abigail A. Christman Hull, Cathy M. Gust, Ann R. Donoghue
Publikováno v:
Journal of Veterinary Internal Medicine
Journal of Veterinary Internal Medicine, Vol 36, Iss 1, Pp 215-226 (2022)
Journal of Veterinary Internal Medicine, Vol 36, Iss 1, Pp 215-226 (2022)
Background Rabacfosadine (RAB, Tanovea‐CA1) is a novel chemotherapy agent conditionally approved for the treatment of lymphoma in dogs. Hypothesis/Objectives To determine the efficacy and safety of RAB in dogs with lymphoma. Animals One hundred and